KORU MEDICAL SYSTEMS INC

Company Overview

KORU Medical Systems (ticker KRMD) designs, manufactures and commercializes large-volume (≥10 ml) mechanical subcutaneous infusion systems (the FREEDOM System) for at‑home and alternate‑site delivery of therapies such as SCIg for PIDD, CIDP and related indications. Revenue is generated from three streams—domestic core, international core (drivers, tubing and needles) and “novel therapies” (clinical trial product and NRE services to biopharma partners)—and 2024–H1 2025 results show double‑digit top‑line growth, expanding gross margins and a narrowing net loss. Operations are concentrated (one U.S. distributor accounted for ~35% of 2024 net revenues; three U.S. and three international distributors ~75%), manufacturing is split between an in‑house NJ facility and a contract manufacturer in Nicaragua, and the company depends on single‑source suppliers and regulatory clearances. Management highlights near‑term liquidity coverage for ~12 months but notes potential need for credit or equity/debt to fund R&D, international expansion and next‑generation product introductions.

Executive Compensation Practices

Given KORU’s position in the Healthcare sector and Medical Instruments & Supplies industry, executive pay is likely a mix of base salary, short‑term cash incentives and equity‑based long‑term incentives tied to product commercialization and growth milestones. Filing details support this: SG&A increases in 2024 were driven in part by bonus accruals and sales commissions, and management is actively hiring commercial leadership (Chief Commercial Officer), suggesting sales‑ and volume‑linked incentives (consumable attach rates, new account wins, international penetration). R&D investment and NRE revenues imply additional performance levers tied to clinical‑trial shipments, regulatory milestones (510(k)/PMA/BLA) and biopharma partnership deliverables; retention and severance items cited in filings point to negotiated retention/termination protections for key technical and commercial hires. With relatively tight cash balances, smaller medical‑device companies like KORU commonly use equity awards (options/RSUs with milestone or time vesting) to align long‑term interests while conserving cash, which can also lead to meaningful dilution if future financings occur.

Insider Trading Considerations

Insider trading activity at KORU is likely to cluster around clearly material operational events: FDA/regulatory submissions and clearances, clinical‑trial milestones and pharma partner NRE win announcements, major distributor contract changes, and financing or equity‑raise news—each can produce outsized share‑price moves given the company’s revenue concentration and small cap profile. Expect regular Section 16 filings from officers/directors; watch for the use of 10b5‑1 trading plans as a common mechanism to allow scheduled sales while avoiding accusations of trading on material nonpublic information. Regulatory and compliance risks in Healthcare (anti‑kickback, privacy/HIPAA, payer coverage decisions) create additional categories of material nonpublic information that will trigger blackout windows and heightened insider restrictions. Finally, because management explicitly ties bonuses and commissions to sales and because future financing is possible, monitor the timing and pattern of insider sales relative to financing announcements—such activity is common but should be evaluated in light of blackout policies, 10b5‑1 plans and public disclosures.